1. Available at: http://www.merck.com/newsroom/press_releases/product/2004_0930.html. Accessed November 22, 2004.
2. Available at: http://www.rheumatology.org/annual/press. Accessed October 24, 2004.
3. Marsa M. What now for pain? With Vioxx off the market, consumers face tough decisions. Los Angeles Times. October 11, 2004:F1-F8.
4. Topol EJ. Failing the public health—rofecoxib, Merck, and the FDA. N Engl J Med. 2004 Oct 21;351(17):1707-9.
5. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539-41.
6. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogne JM. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Chem Med. 2004 May;11(10):1243-52.
7. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol. 2002 Aug 1;165(3):1605-11.
8. Rubinsztajn R, Wronska J, Chazan R. Urinary leukotriene E4 concentration in patients with bronchial asthma and intolerance of non-steriods anti-inflammatory drugs before and after oral aspirin challenge. Pol Arch Med Wewn. 2003 Aug;110(2):849-54.
9. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):369-75.
10. Laufer S. Role of eicosanoids in structural degradation in osteoarthritis. Curr Opin Rheumatol. 2003 Sep;15(5):623-7.
11. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology. 2001;57(5 Suppl 2):S5-7.
12. James MJ, Penglis PS, Caughey GE, Demasi M, Cleland LG. Eicosanoid production by human monocytes: does COX-2 contribute to a self-limiting inflammatory response? Inflamm Res. 2001 May;50(5):249-53.
13. Pommery N, Taverne T, Telliez A, et al. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate can- cer chemotherapy. J Med Chem. 2004 Dec 2;47(25):6195-206.
14. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr;31(2 Suppl 7):12-21.
15. Abou-Issa H, Alshafie G. Celecoxib: a novel treatment for lung cancer. Expert Rev Anti-Cancer Ther. 2004 Oct;4(5):725-34.
16. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Institive. Cancer Res. 2003 Sep 15;63(18):6096-101.
17. Manav M, Su J, Hughes K, Lee HP, Ong CN. Omega-3 fatty acids and selenium as coronary heart disease risk modifying factors in Asian, Indian, and Chinese males. Nutrition. 2004 Nov:20(11-12):967-73.
18. Lugardon S, Lapeyre-Mestre M, Montastrue JL. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Phamacovigilance Database. Eur J Clin Pharmacol. 2004 Nov;60(9):673-77.
19. Feldman M, Cryer B, Rushin K, Betancourt J. A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women. Clin Appl Thromb Hemost. 2001 Jan;7(1):53-7.
20. Kiefer D. Quenching the flames of inflammatory brain aging. Life Extension. September, 2003.
21. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des. 2002;8(19):1695-706.
22. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004 Dec;177(2):235-43.
23. Available at: http://www.pfizer.com/are/news_releases/2004pr/mn_2004_1001.html. Accessed November 7, 2004.
24. Available at: http://www.money.cnn.com/2004/10/15/news/fortune500/pfizer. Accessed November 22, 2004.
25. Available at: http://biz.yahoo.com/ap/041018/pfizer_celebrex_study_11.html. Accessed November 22, 2004.
26. Available at: http://www.arthritis.org/resource4s/gettingstarted/default/asp. Accessed October 24, 2004.
27. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsul fonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.
28. Anonymous. Functional Assessment Resource Manual. Great Smokies Diagnostic Laboratory, Asheville, NC. Winter 2002:N41-N56.
29. Horrobin DF. Prostaglandin E1: physiological significance and clinical use. Wien Klin Wochenschr. 1988 Jul 15;100(14):471-7.
30. Ferretti A, Flanagan VP, Reeves VB. Occurrence of prostaglandin E3 in human urine as a result of marine oil ingestion: gas chromatographic-mass spectrometric evidence. Biochim Biophys Acta. 1988 Apr 15;959(3):262-8.
31. Mayatepek E, Paul K, Leichsenring M, et al. Influence of dietary (n-3)-polyunsaturated fatty acids on leukotriene B4 and prostaglandin E2 synthesis and course of experimental tuberculosis in guinea pigs. Infection. 1994 Mar;22(2):106-12.
32. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991 Sep;54(3):438- 63.
33. Hendler SS, Rorvik D. PDR for Nutritional Supplements, 1st Ed. Montvale, NJ: Medical Economics Co; 2001:149.
34. Manthey JA, Grohmann K, Montanari A, Ash K, Manthey CL. Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes. J Nat Prod. 1999 Mar;62(3):441-4.
35. Ishiwa J, Sato T, Mimaki Y, et al. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol. 2000 Jan;27(1):20- 5.
36. Lin N, Sato T, Takayama Y, et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol. 2003 Jun 15;65(12):2065-71.
37. Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT. Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkin- son’s disease. Neuroreport. 2001 Dec 4;12(17):3871-5.
38. Hendler SS, Rorvik D. PDR for Nutritional Supplements, 1st Ed. Montvale, NJ: Medical Economics Co; 2001:149.
39. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med. 1987 Nov 20;83(5A):29-34.
40. Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimit-telforschung. 1998 May;48(5):469-74.
41. Rizzo R, Grandolfo M, Godeas C, Jones KW, Vittur F. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. J Exp Zool. 1995 Sep 1;273(1):82-6.
42. Murav'ev I, Venikova MS, Pleskovskaia GN, Riazantseva TA, Sigidin I. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter. 1991 Mar-Apr;(2):37-9.
43. Lawrence RM. Methysulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med. 1998;1:50.
44. Jacob SW, Lawrence RM, Zucker M. The Miracle of MSM. New York: Berkley Books, 1999.
45. Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmthane and their combination in osteoarthritis. Clin Drug Invest. 2004 Jun;24(6):353-63.
46. Takase B, Maruyama T, Kurita A, et al. Arachidonic acid metabolites in acute myocardial infarction. Angiology. 1996 Jul;47(7):649-61.
47. Foral PA, Nystrom KK, Wilson AF, Christensen CM. Gastrointestinal-related adverse effects of COX-2 inhibitors. Drugs Today. 2003 Dec;39(12):939-48.
48. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther. 2004 Apr 1;19(7):755-64.
Theaflavins
1. Beltz LA, Bayer DK, Moss AL, Simet IM. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem. 2006 Sep;6(5):389-406.
2. Cameron AR, Anton S, Melville L, et al. Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a. Aging Cell. 2008 Jan;7(1):69-77.
3. Yung LM, Leung FP, Wong WT, et al. Tea polyphenols benefit vascular function. Inflammopharmacology. 2008 Sep 26.
4. Benelli R, Vene R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem. 2002 Jan;383(1):101-5.
5. Aneja R, Odoms K, Denenberg AG, Wong HR. Theaflavin, a black tea extract, is a novel anti-inflammatory compound. Crit Care Med. 2004 Oct;32(10):2097-103.
6. Kebschull M, Demmer R, Behle JH, et al. Granulocyte chemotactic protein 2 (gcp-2/cxcl6) complements interleukin-8 in periodontal disease. J Periodontal Res. 2008 Oct 7.
7. Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in COPD and asthma: similarities and differences. Nihon Kokyuki Gakkai Zasshi. 2008 Jun;46(6):443-7.
8. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol. 2000 Nov;1:181-8.
9. Lyn-Cook BD, Rogers T, Yan Y, et al. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer. 1999;35(1):80-6.
10. Chen YC, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. Inhibition of TPA-induced protein kinase C and transcription activator protein-1 binding activities by theaflavin-3,3’-digallate from black tea in NIH3T3 cells. J Agric Food Chem. 1999 Apr;47(4):1416-21.
11. Lin YL, Tsai SH, Lin-Shiau SY, Ho CT, Lin JK. Theaflavin-3,3’-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur J Pharmacol. 1999 Feb 19;367(2-3):379-88.
12. Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3’-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem Pharmacol. 2000 Feb 15;59(4):357-67.
13. Liang YC, Tsai DC, Lin-Shiau SY, et al. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced inflammatory skin edema and ornithine decarboxylase activity by theaflavin-3,3’-digallate in mouse. Nutr Cancer. 2002;42(2):217-23.
14. Lin JK. Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways. Arch Pharm Res. 2002 Oct;25(5):561-71.
15. Sugatani J, Fukazawa N, Ujihara K, et al. Tea polyphenols inhibit acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and platelet-activating factor-induced platelet aggregation. Int Arch Allergy Immunol. 2004 May;134(1):17-28.
16. Cai F, Li CR, Wu JL, et al. Theaflavin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-inflammatory effect and modulation of STAT-1. Mediators Inflamm. 2006;2006(5):30490.
17. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem. 2004 Feb 1;91(2):232-42.
18. Siddiqui IA, Raisuddin S, Shukla Y. Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Lett. 2005 Sep 28;227(2):125-32.
19. Siddiqui IA, Zaman N, Aziz MH, et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis. 2006 Apr;27(4):833-9.
20. Zykova TA, Zhang Y, Zhu F, Bode AM, Dong Z. The signal transduction networks required for phosphorylation of STAT1 at Ser727 in mouse epidermal JB6 cells in the UVB response and inhibitory mechanisms of tea polyphenols. Carcinogenesis. 2005 Feb;26(2):331-42.
21. Cai F, Li C, Wu J, et al. Modulation of the oxidative stress and nuclear factor kappaB activation by theaflavin 3,3’-gallate in the rats exposed to cerebral ischemia-reperfusion. Folia Biol (Praha). 2007;53(5):164-72.
22. Das D, Mukherjee S, Das AS, Mukherjee M, Mitra C. Aqueous extract of black tea (Camellia sinensis) prevents ethanol+cholecystokinin-induced pancreatitis in a rat model. Life Sci. 2006 Apr 4;78(19):2194-203.
23. Ukil A, Maity S, Das PK. Protection from experimental colitis by theaflavin-3,3’-digallate correlates with inhibition of IKK and NF-kappaB activation. Br J Pharmacol. 2006 Sep;149(1):121-31.
24. Banerjee S, Manna S, Saha P, Panda CK, Das S. Black tea polyphenols suppress cell proliferation and induce apoptosis during benzo(a)pyrene-induced lung carcinogenesis. Eur J Cancer Prev. 2005 Jun;14(3):215-21.
25. Banerjee S, Manna S, Mukherjee S, et al. Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression. Asian Pac J Cancer Prev. 2006 Oct;7(4):661-6.
26. Banerjee S, Maity P, Mukherjee S, et al. Black tea prevents cigarette smoke-induced apoptosis and lung damage. J Inflamm (Lond). 2007;43.
27. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res. 2007 Jan 15;73(2):348-58.
28. Karori SM, Ngure RM, Wachira FN, Wanyoko JK, Mwangi JN. Different types of tea products attenuate inflammation induced in Trypanosoma brucei infected mice. Parasitol Int. 2008 Sep;57(3):325-33.
29. Maron DJ, Lu GP, Cai NS, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. 2003 Jun 23;163(12):1448-53.
30. Duffy SJ, Keaney JF, Jr., Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001 Jul 10;104(2):151-6.
31. Steptoe A, Gibson EL, Vuononvirta R, et al. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. Atherosclerosis. 2007 Aug;193(2):277-82.
32. Marjanovic JA, Stojanovic A, Brovkovych VM, Skidgel RA, Du X. Signaling-mediated functional activation of inducible nitric-oxide synthase and its role in stimulating platelet activation. J Biol Chem. 2008 Oct 24;283(43):28827-34.
33. Shashkin PN, Brown GT, Ghosh A, Marathe GK, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol. 2008 Sep 1;181(5):3495-502.
34. Dordelmann C, Telgmann R, Brand E, et al. Functional and structural profiling of the human thrombopoietin gene promoter. J Biol Chem. 2008 Sep 5;283(36):24382-91.
35. Kalra N, Seth K, Prasad S, et al. Theaflavins induced apoptosis of LNCaP cells is mediated through induction of p53, down-regulation of NF-kappa B and mitogen-activated protein kinases pathways. Life Sci. 2007 May 16;80(23):2137-46.
36. Park AM, Dong Z. Signal transduction pathways: targets for green and black tea polyphenols. J Biochem Mol Biol. 2003 Jan 31;36(1):66-77.
37. Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res. 2007 Nov;48(11):2334-43.
38. Available at: http://www.medicalnewstoday.com/articles/67591.php. Accessed October 23, 2008.
39. WG0401 protective against generalized inflammation in a human study. Unpublished data, WellGen, Inc.; 2007.
40. McGuirk P, Higgins SC, Mills KH. Regulatory cells and the control of respiratory infection. Curr Allergy Asthma Rep. 2005 Jan;5(1):51-5.
41. Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev. 2007 Dec;65(12 Pt 2):S173-6.
42. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007 Dec;65(12 Pt 2):S253-9.
43. Ordovas J. Diet/genetic interactions and their effects on inflammatory markers. Nutr Rev. 2007 Dec;65(12 Pt 2):S203-7.
44. Gillies PJ. Preemptive nutrition of pro-inflammatory states: a nutrigenomic model. Nutr Rev. 2007 Dec;65(12 Pt 2):S217-20.
45. Lindi V, Schwab U, Louheranta A, et al. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol Genet Metab. 2003 May;79(1):52-60.
46. Tsitouras PD, Gucciardo F, Salbe AD, Heward C, Harman SM. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm Metab Res. 2008 Mar;40(3):199-205.
47. Blazovics A, Hagymasi K, Pronai L. Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases. Orv Hetil. 2004 Dec 12;145(50):2523-9.
48. Chen HW, Lee JY, Huang JY, et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 2008 Sep 15;68(18):7428-38.
49. Caramia G. Omega-3: from cod-liver oil to nutrigenomics. Minerva Pediatr. 2008 Aug;60(4):443-55.
50. Crujeiras AB, Parra D, Milagro FI, et al. Differential expression of oxidative stress and inflammation related genes in peripheral blood mononuclear cells in response to a low-calorie diet: a Nutrigenomics Study. OMICS. 2008 Aug 7.
51. Fernandes G. Progress in nutritional immunology. Immunol Res. 2008;40(3):244-61.
52. Hall AJ, Babish JG, Darland GK, et al. Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry. 2008 May;69(7):1534-47.
53. Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 2008 Jun;19(3):242-7.
54. Kornman K, Rogus J, Roh-Schmidt H, et al. Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept. Nutrition. 2007 Nov;23(11-12):844-52.
55. Kussmann M, Blum S. OMICS-derived targets for inflammatory gut disorders: opportunities for the development of nutrition related biomarkers. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):271-87.
56. Rimbach G, Boesch-Saadatmandi C, Frank J, et al. Dietary isoflavones in the prevention of cardiovascular disease—a molecular perspective. Food Chem Toxicol. 2008 Apr;46(4):1308-19.
Boron
1. Kelly GS. Boron: A review of its nutritional interactions and therapeutic uses. Altern Med Rev. 1997 Jan;2(1):48-56.
2. Available at: www.futureceuticals.com/proprietary/pdf/FruitexBBrochure.pdf. Accessed June 1, 2006.
3. Available at: www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/bor_0040.shtml. Accessed June 1, 2006.
4. Smyth HF Jr, Carpenter CP, Weil CS, Pozzani UC, Striegel JA, Nycum JS. Range-finding toxicity data: List VII. Am Ind Hyg Assoc J. 1969 Sep-Oct;30(5)470-6.
5. Available at: http://swpat.ffii.org/pikta/txt/ep/1001/788/. Accessed June 1, 2006.
6. Schaafsma A, de Vries PJ, Saris WH. Delay of natural bone loss by higher intakes of specific minerals and vitamins. Crit Rev Food Sci Nutr. 2001 May;41(4):225-49.
7. Miggiano GA, Gagliardi L. Diet, nutrition and bone health. Clin Ter. 2005 Jan-Apr;156(1-2):47-56.
8. Nielsen FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J. 1987 Nov;1(5):394-7.
9. Hegsted M, Keenan MJ, Siver F, Wozniak P. Effect of boron on vitamin D deficient rats. Biol Trace Elem Res. 1991 Mar;28(3):243-55.
10. Gaby AR. Natural treatments for osteoarthritis. Altern Med Rev. 1999 Oct;4(5):330-41.
11. Travers RL, Rennie GC, Newnham RE. Boron and arthritis: the result of a double-blind pilot study. J Nutr Med. 1990;1:127–32.
12. Hall IH, Rajendran KG, Chen SY, et al. Anti-inflammatory activity of amine-carboxyboranes in rodents. Arch Pharm (Weinheim). 1995 Jan;328(1):39-44.
13. Rajendran KG, Chen SY, Sood A, Spielvogel BF, Hall IH. The anti-osteoporotic activity of amine-carboxyboranes in rodents. Biomed Pharmacother. 1995;49(3):131-40.
14. Hall IH, Starnes CO, McPhail AT, et al. Anti-inflammatory activity of amine cyanoboranes, amine carboxyboranes, and related compounds. J Pharm Sci. 1980 Sep;69(9):1025-9.
15. Helliwell TR, Kelly SA, Walsh HP, et al. Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone. 1996 Feb;18(2):151-7.
16. Newnham RE. Essentiality of boron for healthy bones and joints. Environ Health Perspect. 1994 Nov;102 Suppl 7:83-5.
17. Zhang Z-F, Winton MI, Rainey C, et al. Boron is associated with decreased risk of human prostate cancer. FASEB J. 2001;15:A1089.
18. Faloon W, Strum S. Does PSA promote prostate cancer? Life Extension. June, 2005: 7-13.
19. Gallardo-Williams MT, Chapin RE, King PE, et al. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma(LNCaP) tumors in nude mice. Toxicol Pathol. 2004 Jan-Feb;32(1):73-8.
20. Penland JG. The importance of boron nutrition for brain and psychological function. Biol Trace Elem Res. 1998;66(1-3):299-317.
21. Penland JG. Dietary boron, brain function, and cognitive performance. Environ Health Perspect. 1994 Nov;102 Suppl 7:65-72.
22. Scorei R, Cimpoiasu VM, Iordachescu D. In vitro evaluation of the antioxidant activity of calcium fructoborate. Biol Trace Elem Res. 2005 Nov;107(2):127-34.
|